Longitudinal Evaluation of Cytopenias in the Renal Transplant Population

• Authors: Aileen C Johnson, Emory University; Geeta Karadkhele, Emory University; Wairimu Magua, Emory University; Payaswini Vasanth, Emory University; Christian Larsen, Emory University
• Journal Title: Transplantation Direct
• Volume: Volume 8, Number 6
• Publisher: Wolters Kluwer Health, Inc. | 2022-05-26, Pages E1339-E1339
• Type of Work: Article | Final Publisher PDF
• Publisher DOI: http://doi.org/10.1097/TXD.0000000000001339
• Subjects: Health Sciences, Medicine and Surgery
• Keywords: Cytopenias; Belatacept patients

Abstract

Background. Cytopenias, a common complication for immunosuppressed patients, are known to be associated with adverse transplant outcomes. However, there is little information on cytopenias in recipients treated with the costimulation blockade agent, belatacept. Methods. We compared cytopenia incidence and manifestations in patients undergoing kidney transplant at Emory University Hospital on tacrolimus and belatacept. To reduce selection bias, the tacrolimus group was narrowed to include only patients eligible for belatacept. Results. Of 1651 patients transplanted between 2009 and 2019, 187 (11%) experienced severe anemia, 309 (19%) experienced leukopenia, and 62 (4%) thrombocytopenia. On multivariable regressions, deceased-donor transplant, cytomegalovirus viremia, and thymoglobulin treatment were associated with risk of developing leukopenia, anemia, and thrombocytopenia. High-risk cytomegalovirus status was also associated with development of leukopenia and anemia. Additionally, azathioprine was associated with development of anemia, and both tacrolimus therapy and Caucasian race were associated with thrombocytopenia. Longitudinal quantifications of hematologic cell lines over the first-year posttransplant were extracted from generalized linear models fit using splines. Only hemoglobin range was significantly different between groups (greater in belatacept patients). Plots of mean cell count for each group suggest an earlier recovery from posttransplant anemia in belatacept patients. Conclusions. Belatacept patients are not at increased risk of cytopenia but may have improved recovery from posttransplant anemia.